ATE197145T1 - Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane - Google Patents

Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane

Info

Publication number
ATE197145T1
ATE197145T1 AT96200393T AT96200393T ATE197145T1 AT E197145 T1 ATE197145 T1 AT E197145T1 AT 96200393 T AT96200393 T AT 96200393T AT 96200393 T AT96200393 T AT 96200393T AT E197145 T1 ATE197145 T1 AT E197145T1
Authority
AT
Austria
Prior art keywords
alkyl
tetrahydronaphtahline
aminochromanes
amino
substituted
Prior art date
Application number
AT96200393T
Other languages
English (en)
Inventor
Craig S Hoechstetter
Diane L Huser
John M Schaus
Robert D Titus
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE197145T1 publication Critical patent/ATE197145T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Lubricants (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AT96200393T 1991-02-08 1992-02-03 Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane ATE197145T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65358391A 1991-02-08 1991-02-08

Publications (1)

Publication Number Publication Date
ATE197145T1 true ATE197145T1 (de) 2000-11-15

Family

ID=24621480

Family Applications (2)

Application Number Title Priority Date Filing Date
AT92300887T ATE151419T1 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphthaline
AT96200393T ATE197145T1 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphtahline und 3-aminochromane

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT92300887T ATE151419T1 (de) 1991-02-08 1992-02-03 Ringsubstituierte 2-amino-1,2,3,4- tetrahydronaphthaline

Country Status (26)

Country Link
US (2) US5426226A (de)
EP (2) EP0712837B1 (de)
JP (1) JP3283892B2 (de)
KR (1) KR100219995B1 (de)
CN (2) CN1036392C (de)
AT (2) ATE151419T1 (de)
AU (2) AU653197B2 (de)
BR (1) BR9200426A (de)
CA (1) CA2060815C (de)
CZ (1) CZ288067B6 (de)
DE (2) DE69218813T2 (de)
DK (2) DK0712837T3 (de)
ES (2) ES2153071T3 (de)
FI (1) FI920526L (de)
GR (2) GR3023601T3 (de)
HU (3) HU225163B1 (de)
IE (1) IE920417A1 (de)
IL (3) IL114760A (de)
MX (1) MX9200505A (de)
MY (1) MY116454A (de)
NO (1) NO301825B1 (de)
NZ (2) NZ241495A (de)
PT (1) PT712837E (de)
RU (2) RU2057751C1 (de)
YU (1) YU48927B (de)
ZA (1) ZA92767B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0471515B1 (de) * 1990-08-15 1997-03-05 Eli Lilly And Company Ring-substituierte 2-Amino-1,2,3,4-tetra-hydronaphthaline, 3-Aminochromane und 3-Aminothiochromane
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto
US5434174A (en) * 1992-07-17 1995-07-18 Eli Lilly And Company Isoxazole derivatives for the treatment of irritable bowel syndrome
EP0697894A4 (de) * 1993-03-31 1996-05-01 Univ Pennsylvania Dopamin d-3 und serotonin (5-ht 1a) rezeptor-liganden und bildgebunde mittel
IL110857A0 (en) * 1993-09-09 1994-11-28 Lilly Co Eli Cessation of tobacco use
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
CA2288897A1 (en) * 1997-04-30 1998-11-05 Clint Duane Walker Aminotetralins as 5-ht1d.alpha. agonists
US6355674B1 (en) 1997-04-30 2002-03-12 Eli Lilly And Company Aminotetralins as 5-HT1D α Agonists
IL133080A0 (en) 1997-07-01 2001-03-19 Pfizer Sertraline salts and sustained-release dosage forms of sertraline
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
BR9913503A (pt) 1998-09-09 2002-01-29 Ishihara Sangyo Kaisha Derivados de benzeno-fundidos úteis como herbicidas
FR2792529B1 (fr) * 1999-04-26 2001-09-28 Sod Conseils Rech Applic Nouvelles compositions pharmaceutiques comprenant des derives de 2-isoxazole-8-aminotetralines
US6792563B1 (en) * 2000-04-28 2004-09-14 Intel Corporation Method and apparatus for bus activity tracking
EP1474141A1 (de) * 2002-02-13 2004-11-10 Pharmagene Laboratories Ltd 5-ht2b rezeptor antagonisten
SE0301796D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use II
SE0301794D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use III
SE0301798D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use IV
SE0301795D0 (sv) * 2003-06-19 2003-06-19 Astrazeneca Ab New use I
RU2377556C1 (ru) * 2008-04-02 2009-12-27 ФГУП "Научно-исследовательский институт прикладной акустики" Способ установления отличительных признаков в химическом составе моногенных линий подсолнечника

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ192641A (en) * 1979-01-26 1984-10-19 Hoffmann La Roche Substituted acetophenones and pharmaceutical compositions
SE8004002L (sv) * 1980-05-29 1981-11-30 Arvidsson Folke Lars Erik Terapeutiskt anvendbara tetralinderivat
US4801605A (en) * 1986-08-29 1989-01-31 Ciba-Geigy Corporation 3-amino-dihydro-[1]-benzopyrans and benzothiopyrans
SE8605504D0 (sv) * 1986-12-19 1986-12-19 Astra Laekemedel Ab Novel chroman derivatives
DE3719924A1 (de) * 1986-12-22 1988-06-30 Bayer Ag 8-substituierte 2-aminotetraline
US5214156A (en) * 1988-03-25 1993-05-25 The Upjohn Company Therapeutically useful tetralin derivatives
CA1335591C (en) * 1988-05-23 1995-05-16 James Arthur Nixon Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
CA1335106C (en) * 1989-02-27 1995-04-04 John Mehnert Schaus Ring-substituted 2-amino-1,2,3,4-tetra-hydronaphthalenes
FR2647365B1 (fr) * 1989-05-24 1991-08-30 Inst Francais Du Petrole Catalyseur multifonctionnel pour le traitement des gaz d'echappement des moteurs a combustion interne, contenant de l'uranium, au moins un promoteur de l'uranium et au moins un metal precieux et sa preparation
SE8901889D0 (sv) * 1989-05-26 1989-05-26 Astra Ab Novel 8-substituted-2-aminotetralines
JP2785879B2 (ja) * 1989-05-31 1998-08-13 ジ・アップジョン・カンパニー 治療学的に有用な２―アミノテトラリン誘導体
DE3919624A1 (de) * 1989-06-15 1990-12-20 Boehringer Ingelheim Kg Neue 2,5-diaminotetraline, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
CA2028341A1 (en) * 1989-10-23 1991-04-24 Junichi Sato 5-substituted-2,4-diphenylpyrimidine derivatives, their production and use
US5420151A (en) * 1989-12-22 1995-05-30 Aktiebolaget Astra Chroman derivatives
SE8904361D0 (sv) * 1989-12-22 1989-12-22 Astra Ab New chroman and thiochroman derivatives
EP0471515B1 (de) * 1990-08-15 1997-03-05 Eli Lilly And Company Ring-substituierte 2-Amino-1,2,3,4-tetra-hydronaphthaline, 3-Aminochromane und 3-Aminothiochromane
IL114760A (en) * 1991-02-08 1997-11-20 Lilly Co Eli Ring-substituted-2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes intermediates thereto

Also Published As

Publication number Publication date
CA2060815A1 (en) 1992-08-09
GR3023601T3 (en) 1997-08-29
HU9500495D0 (en) 1995-04-28
ES2102456T3 (es) 1997-08-01
RU2057751C1 (ru) 1996-04-10
HU211848A9 (en) 1995-12-28
CZ288067B6 (cs) 2001-04-11
NO301825B1 (no) 1997-12-15
PT712837E (pt) 2001-03-30
ATE151419T1 (de) 1997-04-15
HU221184B1 (en) 2002-08-28
JPH04327579A (ja) 1992-11-17
CN1036392C (zh) 1997-11-12
MY116454A (en) 2004-02-28
EP0712837A2 (de) 1996-05-22
HUT72659A (en) 1996-05-28
EP0498590B1 (de) 1997-04-09
EP0498590A1 (de) 1992-08-12
YU12992A (sh) 1995-01-31
NO920489D0 (no) 1992-02-06
KR920016454A (ko) 1992-09-24
AU8168794A (en) 1995-02-23
AU664520B2 (en) 1995-11-16
CZ33292A3 (en) 1993-03-17
DE69218813D1 (de) 1997-05-15
IL100858A0 (en) 1992-11-15
RU94044322A (ru) 1996-10-10
RU2105756C1 (ru) 1998-02-27
IL114760A (en) 1997-11-20
ES2153071T3 (es) 2001-02-16
IE920417A1 (en) 1992-08-12
US5426226A (en) 1995-06-20
CA2060815C (en) 2002-05-14
DK0498590T3 (da) 1997-05-05
EP0712837B1 (de) 2000-10-25
ZA92767B (en) 1993-08-03
CN1140167A (zh) 1997-01-15
CN1063870A (zh) 1992-08-26
YU48927B (sh) 2002-12-10
MX9200505A (es) 1992-08-01
DE69231538D1 (de) 2000-11-30
NO920489L (no) 1992-08-10
US5571942A (en) 1996-11-05
GR3035190T3 (en) 2001-04-30
AU1077592A (en) 1992-08-13
BR9200426A (pt) 1992-10-13
AU653197B2 (en) 1994-09-22
FI920526A7 (fi) 1992-08-09
NZ241495A (en) 1994-10-26
CN1052218C (zh) 2000-05-10
IE970857A1 (en) 2000-02-23
JP3283892B2 (ja) 2002-05-20
HU225163B1 (en) 2006-07-28
DE69231538T2 (de) 2001-06-07
KR100219995B1 (ko) 1999-09-01
IL114760A0 (en) 1995-11-27
DE69218813T2 (de) 1997-08-14
NZ264302A (en) 1995-04-27
EP0712837A3 (de) 1997-05-21
FI920526A0 (fi) 1992-02-07
DK0712837T3 (da) 2000-11-20
HU9200396D0 (en) 1992-04-28
FI920526L (fi) 1992-08-09
HUT62569A (en) 1993-05-28
IL100858A (en) 1996-03-31

Similar Documents

Publication Publication Date Title
DE69231538D1 (de) Ringsubstituierte 2-Amino-1,2,3,4-tetrahydronaphtahline und 3-Aminochromane
ZA881377B (en) Process for improving the photochemical stability of dyeings on polyester fibre materials
IL106677A0 (en) Novel 7-(substituted)-8-(substituted-9-(substituted amino)-6-demethyl-6-deoxytetracyclines
IT1250749B (it) Composti eterociclici ad attivita' a ii antagonista
EP0456833A4 (en) Immunosuppressant and process for preparing the same
HU9202199D0 (en) A new medical preparative containing benzomorphane
ZA931724B (en) New derivatives of beta-amino acids
FI875145A0 (fi) Kondenserade heterocykliska tetrahydroaminokinoliner och beslaektade foereningar, en metod foer deras framstaellning och deras anvaendning som mediciner.
DE59305733D1 (de) Verfahren zur Herstellung von 1,3-Difluorbenzol
NO950574L (no) Akronycinanaloger
HUP9700103A2 (hu) 1,3,4-Tiadiazol-származékok és eljárás előállításukra
DE59300078D1 (de) Salze von 3-(cis-2,6-Dimethylpiperidino)-sydnonimin.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee